The KEYNOTE-012 trial [80] demonstrated in an early-phase the potential application of anti-PD1 therapy with pembrolizumab (humanized IgG4-k monoclonal anybody selective to bind PD1, currently approved by FDA in the US) in 39 patients that were affected by PD-L1 positive refractory advanced gastric cancer with promising overall response (22%, 95% CI 10–39). The gene discussed is CD274; the disease is gastric cancer.